NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.48 +0.49 (+0.62%) GOLD FUTURES
2,343.30 +21.00 (+0.90%) DOW
39,376.59 +320.20 (+0.82%) Bitcoin GBP
49,729.36 +42.01 (+0.08%)
Aurora Cannabis Inc. (ACB.TO)
| Previous close | 8.86 |
| Open | 8.85 |
| Bid | 9.37 x 0 |
| Ask | 9.39 x 0 |
| Day's range | 8.62 - 9.51 |
| 52-week range | 3.84 - 15.50 |
| Volume | |
| Avg. volume | 2,186,441 |
| Market cap | 511.034M |
| Beta (5Y monthly) | 2.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -79.20 |
| Earnings date | 12 Jun 2024 - 17 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.83 |
PR NewswireAurora Marks First Shipment of Medical Cannabis to the New Zealand Market
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) the Canadian based leading global medical cannabis company, is proud to announce the arrival of Aurora branded medical cannabis products to the New Zealand market. This new line of premium dried flowers represents a significant milestone in medical cannabis accessibility in New Zealand, an emerging market poised for growth.
ZacksAurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?
Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PR NewswireAurora Improves Offerings in Australia with New Range of Premium Dried Flower Products
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is pleased to announce the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia, a premie
